Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASCT-I in Metastatic or Recurrent Solid Tumors
NCT05877651Phase 1Completed
- Sponsor
- HRYZ Biotech
- Start
- Apr 2020
- Primary completion
- Oct 2021
- Modality
- Whole Cell Cancer Vaccines, Allogeneic CAR-T, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of MASCT-I in solid tumor (2 arms), sponsored by HRYZ Biotech. Primary endpoint: Adverse events and serious adverse events related to MASCT-I at 8 weeks. Started Apr 2020; status: completed.
02
Drugs
MASCT-I
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05877651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05877651.